Pharmaceuticals
Senhwa Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer
TAIPEI and SAN DIEGO, Oct. 31, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced today that their first patient has been successfully dosed, in a phase I c...
2022-10-31 19:00
3054
Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022
HONG KONG, Oct. 30, 2022 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") released the Phase Ib clinical results of Ivonescimab (PD-1/VEGF bi-specific, AK112) in combination with etoposide and carboplatin in first-line treatment of extensive-stage small-cell lung cancer(ES-SCLC), in an oral ...
2022-10-31 08:40
2135
GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT Study Interim Analysis during Breast Cancer Awareness Month 45% change in treatment recommendations when using DCISionRT
CALIFORNIA CITY, Calif., Oct. 30, 2022 /PRNewswire/ -- GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx(TM)), a leader in molecular diagnostics and precision medicine, today announced interim results from the AUSPREDICT registry. Data presente...
2022-10-31 05:00
1930
Nuevocor to Present Pre-clinical Data on its Gene Therapy Candidate for LMNA Dilated Cardiomyopathy at American Heart Association Scientific Sessions 2022
SINGAPORE, Oct. 28, 2022 /PRNewswire/ -- Nuevocor, a pre-clinical stage cardiac gene therapy company, announced today that it will present new preclinical data on its adeno-associated virus (AAV) gene therapy forLMNA dilated cardiomyopathy at the American Heart Association (AHA) Scientific Sessio...
2022-10-28 22:30
3305
LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022
The efficacy and mechanism of NASH microbiome-based therapy for liver fibrosis, steatosis, and inflammation have been confirmed in various animal models SEOUL, South Korea, Oct. 28, 2022 /PRNewswire/ -- LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented ne...
2022-10-28 21:00
2525
Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
BOSTON, Oct. 28, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (STAR: 688302), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, today presented their preclinical results of ...
2022-10-28 20:30
2819
NDA for New Second-Line Indication of CAR T-Cell Therapy Product YIKAIDA (Axicabtagene Ciloleucel Injection) Approved for CDE Review
Fosun Kite to Participate in the Fifth CIIE to Showcase New Options in Cell Therapy SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- October 24 brought good news from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) that the NDA for new second-line indication o...
2022-10-28 01:37
2731
WuXi Biologics Provides Corporate Updates
SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today updated its recent corporate progress. Recent Business Milestone Despite the global dynamic situation and funding challeng...
2022-10-27 22:13
3223
Simcere Receives FDA Clearance of Investigational New Drug Application (IND) for Bi-functional Fusion Protein, SIM0237
Second US IND approval this year for the global pharmaceutical group NANJING, China and BOSTON, Oct. 27, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK), an innovative global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the com...
2022-10-27 21:25
2717
Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US
SUZHOU, China, Oct. 27, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 120 subj...
2022-10-27 21:22
2542
Antengene to Host Research and Development Day on November 15th and 17th, 2022
* Virtual English Session: Tuesday, November 15 at 8:30 AM – 12:00 PM Eastern Time November 15 at 9:30 PM – November 16 at 1:00 AM Beijing Time * Hybrid Mandarin Session in Shanghai: Thursday, November 17 at 1:30 PM – 5:30 PM Beijing Time SHANGHAI and HONG KONG, Oct. 26, 2022 /PRNewswire/ -- An...
2022-10-27 11:07
3767
Samsung Biologics Reports Third Quarter 2022 Financial Results
* Recorded consolidated revenue of KRW 873 billion in Q3'22 * Recorded consolidated operating profit of KRW 324.7 billion in Q3'22 * Started partial operations at Plant 4 within 23 months since groundbreaking as previously committed and launched two new development platforms INCHEON, South K...
2022-10-27 07:35
2496
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting
MELBOURNE, Australia and SAN FRANCISCO , Oct. 26, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation f...
2022-10-26 19:25
2831
Yiling Pharmaceutical Exhibiting its Innovative TCM Products during CHEXPO Macau 2022
SHIJIAZHUANG, China, Oct. 26, 2022 /PRNewswire/ -- CHEXPO Macau 2022 was officially opened onOctober 20, 2022. As one of the top 10 TCM enterprises in China, Yiling Pharmaceutical exhibited a number of its patented TCM and health products during the expo. As an international and frontier city of ...
2022-10-26 16:52
2697
ImmVira announced its signing of Series C+ financing and negotiation with further investors for the round
SHENZHEN, China, Oct. 26, 2022 /PRNewswire/ -- ImmVira announced its successful signing of Series-C+ financing transaction documents with the first batch of investors recently. This round of financing was initiated by China Merchants China Direct Investments Limited with participation of Lifebay ...
2022-10-26 14:26
2493
SK bioscience and CEPI Sign Agreement to Develop mRNA Vaccines
* CEPI supports up to 40 mil. USD for early development of mRNA vaccine platform to SK bioscience; up to a further 100 mil. could be made available for late-stage development. * SK bioscience to secure new vaccines and establish pandemic response system * SK bioscience to enhance human healt...
2022-10-25 20:00
3005
FDA Accepts NMP's Clinical Trial Application for Development of NMK89 as Imaging Agent for Cancer Diagnosis
- Clinical Study Set to Begin, Focusing on Diagnostic Use of Theranostics - TOKYO, Oct. 25, 2022 /PRNewswire/ -- Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company inJapan, is pleased to announce that the U.S. Food and Drug Administration (FDA) has recently accepted NMP's ...
2022-10-25 16:00
2052
WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities
* WuXi Biologics adds further capacity and capability for drug product fill & finish, providing global customers with end-to-end integrated solutions for diversified modalities, including mRNA-LNP HANGZHOU, China, Oct. 23, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading gl...
2022-10-24 08:30
2598
SK bioscience Appoints New Executives towards Global Business Growth
* Global experts continue to join SK bioscience, while its U.S. corporate entity is being established * Company plans to strategically invest in personnel, innovation & infrastructure to ensure global competitiveness SEOUL, South Korea, Oct. 21, 2022 /PRNewswire/ -- SK bioscience, a global in...
2022-10-21 20:00
3374
Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States
CAMBRIDGE, Mass., ROTTERDAM and SUZHOU, China, Oct. 20, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, it has successfully completed the dosing of first patient in the global phase I trial of B7H4x4-1BB bispecific antibody HBM7008 inthe United States. This study will eva...
2022-10-20 16:20
2199
Week's Top Stories
Most Reposted
HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 310 media titles]
2026-02-26 09:30
Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 308 media titles]
2026-02-26 19:57
SMU and Fudan Launch Region's First Tech-Focused DBA
[Picked up by 300 media titles]
2026-03-02 09:15Infobip is set to launch AgentOS to orchestrate autonomous AI-driven customer journeys at scale
[Picked up by 289 media titles]
2026-03-02 09:00
Klook's Spring Readiness Index shows how Asia's travelers are preparing for spring travel across Japan, South Korea, and Mainland China
[Picked up by 284 media titles]
2026-03-03 15:49
Most Read
COLUMBIA ASIA HOSPITAL BUKIT JALIL LAUNCHES NEW CATH LAB TO STRENGTHEN HEART CARE SERVICES
2026-03-02 14:24
7738
NYSE Content Update: AI Data Platform DDN Appoints Guido Torrini as Finance Chief
2026-02-24 22:08
7169
